Head and neck cancers

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 7, 2008, Pages 646-695

  Forastiere, Arlene A ^a   Ang, Kie Kian ^a   Brizel, David ^a   Brockstein, Bruce E ^a   Burtness, Barbara A ^a   Cmelak, Anthony J ^a   Colevas, Alexander D ^a   Dunphy, Frank ^a   Eisele, David W ^a   Goepfert, Helmuth ^a   Hicks Jr , Wesley L ^a   Kies, Merrill S ^a   Lydiatt, William M ^a   Maghami, Ellie ^a   Martins, Renato ^a   McCaffrey, Thomas ^a   Mittal, Bharat B ^a   Pfister, David G ^a   Pinto, Harlan A ^a   Posner, Marshall R ^a   Ridge, John A ^a   Samant, Sandeep ^a   Schuller, David E ^a   Shah, Jatin P ^a   Spencer, Sharon ^a   Trotti III, Andy ^a   Weber, Randal S ^a   Wolf, Gregory T ^a   Worden, Frank ^a   more..

^a NONE

Author keywords

Chemotherapy; Glottic; Head and neck cancer; Hypopharynx; Larynx; Nasopharynx; NCCN Clinical Practice Guidelines; Oral cavity; Oropharynx; Radiotherapy; Supraglottic; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROTIRELIN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INCIDENCE; INTERDISCIPLINARY COMMUNICATION; LARYNGECTOMY; LARYNX CANCER; METASTASIS; MONOTHERAPY; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NECK DISSECTION; OROPHARYNX CANCER; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RECURRENT CANCER; REVIEW; SALVAGE THERAPY;

EID: 49649118325     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0051     Document Type: Review

References (84)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
3. Kreimer AR, Clifford GM, Boyle F, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475.
4. Applebaum KM, Furniss CS, Zeka A, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007;99:1801-1810.
5. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
6. Schlecht NF, Burk RD, Adrien L, et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007;213:283-293.
7. Sturgis EM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer 2007;110:1429-1435.
8. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. Springer-Verlag: New York; 2002.
9. Colasanto JM, Prasad F, Nash MA, et al. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology 2005;19:371-382.
10. Schnoll RA, Zhang B, Rue M, et al. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2003;21:355-365.
11. Gritz ER, Carr CR, Rapkin D, et al. Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1993;2:261-270.
12. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
13. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
14. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-850.
15. Furniss CS, McClean MD, Smith JF, et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007;120:2386-2392.
16. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-2611.
17. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
18. Denis F, Garaud F, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
19. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-326.
20. Hitt R, Grau J, Lopez-Pousa A, et al. Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable, locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 5578.
21. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636-8645.
22. Hitt R, Grau J, Lopez-Pousa A, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/ 5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2006;24:Abstract 5515.
23. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
24. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704.
25. Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiation Oncol Biol Phys 2000;48:7-16.
26. Trotti A, Fu K, Pajak T, et al. Long term outcomes of RTOG 90-03: a comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. Int J Radiat Oncol Biel Phys 2005;63:S70-71.
27. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radio-therapy. Radiother Oncol 1992;25:231-241.
28. Pinto LJ, Canary PCV, Araujo CMM, et al. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1990;21:557-562.
29. Kotwall C, Sako K, Razack MS, et al. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987;154:439-442.
30. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-899.
31. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004; 15:638-645.
32. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
33. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
34. Cooper IS, Rowe JD, Newall J. Regional stage IV carcinoma of the nasopharynx treated by aggressive radiotherapy. Int J Radiat Oncol Biol Phys 1983;9:1737-1745.
35. Bailer JW, Mark RI, Abemayor E, et al. Nasopharynx carcinoma: treatment results with primary radiation therapy. Laryngoscope 1992;102:965-972.
36. Johansen LV, Mestre M, Overgaard J. Carcinoma of the nasopharynx: analysis of treatment results in 167 consecutively admitted patients. Head Neck 1992;14:200-207.
37. Sanguineti G, Geara F, Garden A, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int Radiat Oncol Biol Phys 1997;37:985-996.
38. Wang CC. Radiation Therapy for Head and Neck Neoplasms, 3rd ed. New York: Wiley-Liss; 1997:274.
39. Mesic JB, Fletcher GH, Geopfert H. Mega-voltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 1981;7:452.
40. Frezza G, Barbieri F, Emiliani E, et al. Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. Radiother Oncol 1986;5:287-294.
41. Santos IA, Gonzalez CP, Dela Fuente I, et al. Impact of change in the treatment of nasopharyngeat carcinoma: an experience of 30 years. Radiother Oncot 1995;36:121-127.
42. Perez CA, DeVineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271-280.
43. Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx: eighteen years experience with megavoltage radiation therapy. Cancer 1976;37:2605-2612.
44. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317.
45. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyn-geal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738.
46. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer 2005;103:569-575.
47. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576.
48. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33-38.
49. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002;13:1252-1258.
50. Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002;95:2516-2523.
51. Posner MR, Ervin TJ, Miller D, et al. Incidence of hypothyroidism following multimodality treatment for advanced squamous-cell cancer of the head and neck. Laryngoscope 1984;94:451-454.
52. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003:21:92-98.
53. Lo TCM, Wiley AL Jr, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976;126:229-235.
54. Sanchiz F, Milla A, Torner J, et al. Single fraction per day versus two fractions per day vs. radiochemotherapy in the treatment of head and neck cancer. Int J Radiation Oncol Biol Phys 1990;19:1347-1350.
55. Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-2653.
56. Smid L, Lesnicar H, Zakotnik B, et al. Radiotherapy combined with simultaneous chemotherapy with mitomycin C and bleomycin for in-operable head and neck cancer: preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769-775.
57. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
58. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-589.
59. Brizel DM, Albers ME Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
60. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
61. Jeremic B, Shibamoto Y, Milicic N, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464.
62. Munro AJ. An Overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
63. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Onco 1996; 14:838-847.
64. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancer 2000;355:949-955.
65. Bourhis J, Amand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract]. J Clin Oncol 2004;22:Abstract 5505.
66. Pignon JP, le Maîrre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S112-114.
67. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
68. Mell LK, Weichselbaum RR. More on cetuximab in head and neck cancer. N Engl J Med 2007;357:2201-2202; author reply 2202-2203.
69. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864.
70. Garden AS, Harris J, Voke EE, et al. Results of Radiation Therapy Oncology Group 97-03 - a randomized phase II trial of concurrent radiation and Chemotherapy for advanced squamous cell carcinomas of the head and neck: long-term results and late toxicities. Int J Radiat Oncol Biot Phys 2007;69:S140.
71. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
72. Forastiere AA, Merch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs. methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-1251.
73. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
74. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2866-2872.
75. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9: 5813-5824.
76. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
77. Baselga J, Trigo JM, Bourhis J, et al, Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
78. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177.
79. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (Extreme) study [abstract]. J Clin Oncol 2007;25:Abstract 6091.
80. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. [abstract]. J Clin Oncol 2007; 25:Abstract 6013.
81. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) [abstract]. J Clin Oncol 2007;25:Abstract 6012.
82. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
83. Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311-319.
84. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) vs. cisptatin and 5-fluorouracil (CF) versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck [abstract]. Ann Oncol 1994;5:521-526.